High performance biodegradable polymer

trellicell is a resorbable polymer based scaffold that can be used to culture any cell type in large formats

trellicell easily fits for various applications and uses across a wide range of industries such as medical, pharmaceutical, food, artificial tissue regeneration etc for cell culture and tissue engineering.

Applications

We have identified extensive applications for our cell growth scaffolds for the development of unprecedented new applications in many areas. To begin with we are focussing on the following three primary applications areas for trellicell scaffolds.

Our Team

trellicell is being developed by Molekulare Biotechnolgie e.U., Austria based biotechnology company working towards revolutionizing the use of biodegradable polymers for wide variety of cell growth applications. trellicell offers high-performance biodegradable polymers suited to develop many innovative and life changing products for a broad range of industries.

Developed by a team of world class researchers and backed by medtech innovators and investors with extensive industry experience in bringing new products to life, trellicell is set to disrupt the artificial cell growth Industry in coming years.

Prof. Dr. Helmut Schwab

CEO & Founder

Dr. Stefan Zopf

Business Strategy & Investor

Kumari Anshu

Strategy & Growth Manager

Florian Meyer

Project Management & IT

Mission

Solve real life world problems related to health and food by innovating superior polymers.

Vision

To become industry leader in developing biodegradable scaffolds promoting artificial cell growth.

Please contact us via

contact@trellicell.com

Molekulare Biotechnologie e.U.
Mariagrünerstraße 91
8043 Graz
Austria

trellicell technology is utilizing a scaffold composed of specific polymer compounds that deliver the physical properties from polymer, while still being 100% absorbable.

trellicell’s dissolvable properties can be altered to better fit the specific needs. One part is that the speed of the dissolving process can be adjusted upon need.

This acts to provide tissue-level structural support to cells, thus encouraging cell adhesion and proliferation. These are the key factors that enable tissue regeneration. trellicell is utilizing this technology to develop products for the organ growth and regeneration, wound repair, resorbable implants and cultured food.

trellicell also helps in controlled release of substances such as drugs or antibiotics that help in wound repair and healing.

Resorbable polymer scaffolds

According to industry reports, the Global resorbable (bioresorbable) polymers market stood at USD 1.6 billion in 2018 and is projected to reach USD 2.4 billion by 2024, growing at a CAGR of around 7.5% during the forecast period
The global Bioresorbable Scaffolds market is valued at USD 198.1 million in 2020 is expected to reach USD 674 million by the end of 2026, growing at a CAGR of 18.9% during 2021-2026
Resorbable Polymer scaffolds market is projected to record 10.8% CAGR and reach USD 425.5 Million by year 2027

trellicell Net is implants, stents or surface coverage made of a resorbable polymer. It is intended for use in fracture repair and reconstructive procedures, controlled release of drugs as well as for wound healing and repair.

Bone Implants

In the early stages of bone healing trellicell Net preserves fixation. Over time, the implant gradually decomposes, and the stresses are steadily transferred to the healing tissue, Providing continuous support for new tissue growth.

Properties of trellicell-Net for bone implants

Completely biodegraded and absorbed by the body
No toxic residual left in the body
Eliminates need of second surgery for implant removal
Cells attach to the fibers and quickly proliferate while making strong contact with underlying nanofibers, therefore promoting interlayer growth
Better structural design with high specific surface area for cell attachment and regeneration
Low risk, Low cost and more time effective solution as compared to other implants

Drug Delivery

trellicell drug delivery capsules help in controlled release of drugs in the body. These capsules are programmed to release drugs at a precise, predictable time, so that multiple doses of a drug or vaccine can be delivered over an extended time period with just one injection or oral capsule.

Properties of trellicell-Net for drug delivery

Effective release of drugs in the body in a predesigned manner
Eliminates the potential for over or under release of drugs in the body
Need for fewer drug administration
Bioresorbable outer coating of the capsule
No toxic side effects

Resorbable implant market overview

Industry reports indicate that the global bioresorbable implants market is expected to grow at a CAGR of 7.4% to reach a market value of USD 10.5 billion by year 2026
The huge benefit of resorbable implants in terms of low risk of infection, no need of second surgery to remove devices, shorter stay in hospital, less complications after surgery makes it a preferred replacement for traditional implants methods.

Market growth drivers

Rising geriatric population
Growing cases of chronic disease, cardiovascular disease, diabetes, obesity due to changing lifestyle choices such as poor diet and lack of exercise
Increasing incidences of trauma and accidents such as road accident, sports injury, fall etc.
Augmented local manufacturing, high growth of end-user industries and increasing number of domestic companies in various vertical market segments

trellicell resorbable polymer based scaffolds supports growth of cultured meat.

To culture three-dimensional meat, the cells are grown on scaffolds that direct its structure and order. With the help of trellicell resorbable scaffold muscle tissue is developed from the growth medium and organized in a three-dimensional structure for the end product.

Advantage of Cultured meat are

Ethical
Healthy and tasty
Clean and safe food choices
Environmentally and economically sustainable
Scalable/ large scale cultivation possibilities
No animal cruelty

Artificial meat market overview

According to market reports the global cultured meat market is estimated to be valued at USD 214 million in 2025 and is projected to reach USD 593 million by 2032, recording a CAGR of 15.7% from 2025 to 2032
Compared to conventional beef, cell-based beef is estimated to reduce land use by more than 95%, climate change emissions by 74% to 87%, and nutrient pollution by 94%

Market growth drivers

trellicell scaffold with its unique properties prove to be ideal for regenerative growth of tissues and organs. trellicell 3D scaffold structures are designed to provide support to stem cells for organoid growth.

Organoids help in screening the efficacy of drugs against various human diseases. The unique capacity of trellicell Organoids to recapitulate characteristics of the personalized organ they originate from opens up new possibilities for research, drug discovery and development. Testing drugs on 3D bioprinted organs has the potential to optimize and accelerate the drug development process.

Some of the greatest impacts of organoid development are following:

Great alternative to animal testing
Personalized medicine development
Eliminating toxic drugs more quickly so that costly clinical trials can be avoided to save valuable and limited resources
Ability to conduct research and test treatment on a larger scale for speedy and effective drug development

Properties of trellicell scaffold for organ growth

Osteoconductive
Proper mechanical and biological properties
trellicell and its degradation products does not elicit inflammation or toxicity
Easily processable into three dimensional structures
High porosity for reducing diffusion constraints, and increasing surface area and adequate space for extracellular matrix regeneration
The degradation rate of trellicell scaffold matches the rate of tissue regeneration by the cell

Better use of resources

Higher success rate of clinical trials

No more animal testing

Speedy Research and Treatment

Personalized Medicine

Industry Overview

The global organoids market size in 2019 is estimated to be US$ 32 Million. The market is expected to grow at a CAGR of 15% in next 10 years to reach 1.96 billion by 2029.
According to industry reports, the global 3D bioprinting market size is USD 1.4 billion in 2019 and is expected to reach USD 4.2 billion by 2027, expanding at a CAGR of 17.4%
There is a major health crisis in terms of the shortage of organs, as the population is living for longer due to medical advances. Since 2013, the number of patients requiring an organ has doubled, while the actual number of available donor organs has barely moved.

Industry growth drivers

Increase in chronic diseases
Shortage of organs
Growing concerns about animal testing of drugs
Growing focus on personalized, patient specific drugs and medicine
Technological Advancement in the field
Rising R&D investment